Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

B-cell Lymphoma

Lymphosarcoma

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CD19 CART cells. The CD19 CART cells are to be administered on day0,day1,day2.

patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8g/m2/day IV for 2 days.

CD19 CART cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.

CD19 CART

geng tian

This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor 19 (CD19 CART) cells in relapsed and refractory patients with CD19+ B cell lymphoma.

This is a study for the patients with B cell lymphoma. Maximum tolerated dose climbing test is expected into the group of 9 cases of patients. And Phase II expected into the group of 11 subjects, selected the above safe dose, carrying out a research into the clinical effectiveness. Subjects will be collected their T cells and modify them, the modification is a genetic change, that CD19:4-1BB:CD28:CD3 modified T cells, in order to tells the T cells to recognize their target tumor cells and potentially kill them, but not other normal cells in the subject's body. The CART cells will then be expanded in vitro and then administered to subjects. The purpose of this study is observe the MTD and to assess the safety and feasibility of CART cells in the patients with relapsed and refractory CD19+ B cell lymphoma.

CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.

Phase I/II Study of CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.

monitor the occurence of study related adverse events

CD19 CART vector sequences will be performed by Q-PCR

The Beijing Pregene Science and Technology Company, Ltd.

Shenzhen Second People's Hospital

Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Hematologic Diseases

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Acute Graft Versus Host Disease

After 6 days of pre-chemotherapy, patients in study group will be injected with CD19CART cell at the dose of 5×10\^4 cells/kg in 36-96 hours

Lixing Wang, M.D.

Li Yu, M.D. Ph.D.

This study is a single-arm, open label, phase I clinical trial to evaluate the safety and feasibility of CD19CAR-T in treatment of relapsed / refractory acute lymphoblasic leukemia.

Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia

the recovery rate of patients consists of complete recovery rate and partial recovery rate of patients being treated with CD19 CAR-T

Shenzhen University General Hospital

Chinese PLA General Hospital

Professor

Lixing Wang, MD

Lixing Wang, M.D

This study is a single-arm, open label, phase I clinical trial to evaluate the safety and feasibility of CD19CAR-T in treatment of relapsed / refractory non-hodgkin lymphoma

Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma

Shenzhen University

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.	NCT03146533	B Cell Lymphoma	Fludarabine Cyclophosphamid... CD19 CART	18 Years - 70 Years	Shenzhen Second People's Hospital
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia	NCT04012879	Relapsed Acute ... Refractory Acut...	CD19 CART	18 Years - 65 Years	Chinese PLA General Hospital
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma	NCT04012892	Relapsed Non-Ho... Refractory Non-...	CD19 CART	18 Years - 65 Years	Chinese PLA General Hospital
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.	NCT03146533	B Cell Lymphoma	Fludarabine Cyclophosphamid... CD19 CART	18 Years - 70 Years	Shenzhen Second People's Hospital
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia	NCT04012879	Relapsed Acute ... Refractory Acut...	CD19 CART	18 Years - 65 Years	Chinese PLA General Hospital
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma	NCT04012892	Relapsed Non-Ho... Refractory Non-...	CD19 CART	18 Years - 65 Years	Chinese PLA General Hospital

Spots Global Cancer Trial Database for cd19 cart

Every month we try and update this database with for cd19 cart cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for cd19 cart

Every month we try and update this database with for cd19 cart cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for cd19 cart cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.